Abstract��OBJECTIVE To evaluate the current clinical application of ambroxol hydrochloride injection and promote its rational use. METHODS Based on the Hospital Prescription Analysis Cooperation Project, 160-day prescription data about ambroxol hydrochloride injection from 2010 to 2013 was sampled randomly from the database of 82 general hospitals in six cities including Beijing, Shanghai, Guangzhou, Hangzhou, Chengdu, and Tianjin. According to the drug instruction, relevant guidelines, expert consensus, and literature, the clinical use of ambroxol hydrochloride injection was analyzed. RESULTS Within the scope of sampling time, there were 2.67 million prescriptions of ambroxol hydrochloride injection, and 14.01 million ampoules(15 mg per ampoule) were used clinically. According to the percentage of prescription complying with the drug instruction, the six cities were ranked in descending order as follows:Hangzhou(28.03%) > Chengdu(26.25%) > Shanghai(14.66%) > Guangzhou(9.38%) > Beijing(7.72%) > Tianjin(3.98%). However, various off-label uses were found in administration route, dosage, and indications. CONCLUSION Off-label use of ambroxol hydrochloride injection is common in clinic, which needs to be paid great attention to and to be standardized.
��ٻٻ,�Ų�,����,÷��. ע�������ᰱ�������ٴ�Ӧ����״��˼��[J]. �й�ҩѧ��־, 2015, 50(9): 816-820.
FAN Qian-qian, ZHANG Bo, LI Da-kui, MEI Dan(. Current Clinical Application of Ambroxol Hydrochloride Injection and Consideration on the Rational Drug Use. Chinese Pharmaceutical Journal, 2015, 50(9): 816-820.
CHEN X Q, JIN Y Y, TANG G. New Pharmacology (�±�ҩ��ѧ) . 17th ed. Beijing:People��s Medical Publishing House, 2011.
[2]
DISSE B G, ZIEGLER H W. Pharmacodynamic mechanism and therapeutic activity of ambroxol in animal experiments . Respiration, 1987, 51(suppl 1):15-22.
[3]
SEIFART C, CLOSTERMANN U, SEIFART U, et al. Cell-specific modulation of surfactant proteins by ambroxol treatment . Toxicol Appl Pharm, 2005, 203(1):27-35.
[4]
GIBBS B F, SCHMUTZLER W, VOLLRATH I B, et al. Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells . Inflamm Res, 1999, 48(2):86-93.
[5]
NOWAK D, ANTCZAK A, KROL M, et al. Antioxidant properties of ambroxol . Free Radic Bio Med, 1994, 16(4):517-522.
[6]
YANG C W, ZHANG Z X, TU W J, et al. Clinical study of ambroxol��s effect on cefoperazone��s transport into pulmonary . J Clin Pulmon Med (�ٴ��ο���־), 2008, 13(6):682-685.
[7]
GAIDA W, KLINDER K, ARNDT K, et al. Ambroxol, a Nav1. 8-preferring Na+ channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain . Neuropharmacology, 2005, 49(8):1220-1227.
[8]
MALERBA M, RAGNOLI B. Ambroxol in the 21st century:Pharmacological and clinical update . Expert Opin Drug Metab Toxicol, 2008,4(8):1119-1129.
[9]
ZHAO L, WEN A D, WU C G, et al. Evaluation of efficacy and safety of injective ambroxol hydrochloride . J Fourth Mil Med Univ(���ľ�ҽ��ѧѧ��), 2004, 25(2):189-192. TANG S F, ZHU H C, LI H Q, et al. Clinical observation of ambroxol hydrochloride inhalation treatment in children bronchial pneumonia . Guide Chin Med (�й�ҽҩָ��), 2008, 6(12):49. CHANG M, DU H Q, HU R G. Observation of the efficacy of ambroxol hydrochloride inhalation treatment in the acute exacerbation period of chronic obstructive pulmonary disease . Hebei Med J (�ӱ�ҽҩ), 2010, 32(13):1742-1743. LUO H. The clinical observation on ambroxol hydrochloride inhalation treatment of 58 cases of children pneumonia . J Pediatr Pharm(����ҩѧ��־), 2011, 17(3):29-31. YUAN Y C, YIN B L, ZHOU W J. Observation of the efficacy of megadose Mucosolvan in patients with acute respiratory distress syndrome after extracorporeal circulation . Chin J Gerontology (�й�����ѧ��־), 2010, 30(9):1297-1298. SUN Z M, YAO Y, CHEN T J, et al. Application of megadose ambroxol in bundle treatment of severe pneumonia. . Chin J Nosocomiol (�л�ҽԺ��Ⱦѧ��־), 2011, 21(18):3941-3942. DENG Q J. Clinical study of megadose ambroxol hydrochloride in AECOPD patients with respiratory failure . J Clin Pulmon Med(�ٴ��ο���־), 2012, 17(4):719-720. Chinese Medical Association. Clinical Diagnosis And Treatment Guideline:Respirology(�ٴ�����ָ�ϡ���������ѧ�ֲ�). Beijing: People��s Medical Publishing House, 2009. WANG T Y. Expert consensus on lung protection in perioperative period of thoracic surgery . Chin J Surg (�л������־), 2009, 47(18):1361-1364. HU B J, HE L X, YIN S J, et al. Cohort study of hospital acquired lower respiratory tract infections in Shanghai . Chin J Infect Chemoth (�й�����Ⱦ������־), 2002, 2(2):74-77. SMETANA G W, LAWRENCE V A, CORNELL J E, et al. Preoperative pulmonary risk stratification for noncardiothoracic surgery:Systematic review for the American College of Physicians . Ann Intern Med, 2006, 144(8):581-595. CHEN Q. Analysis of the efficacy of ambroxol and pulmonary surfactant in preventing respiratory distress syndrome of newborn . J Clin Pulmon Med (�ٴ��ο���־), 2013, 18(5):917-918. GAO W. Clinical observation of ambroxol hydrochloride in the prevention of neonatal respiratory distress syndrome . Chin Pharm J(�й�ҩѧ��־), 2008, 43(12):959-960. YU G P, HUANG B, CHEN G Q. Lung protection after thoracic surgery and its mechanism of ambroxol in elderly patients with esophageal cancer . Chin J Thorac Cardiovasc Surg(�л�����Ѫ�������־), 2013, 29(11):703-704. JI C Y, FANG W T. Ambroxol hydrochloride for lung protection in perioperative period of thoracic surgery . Chin J Thorac Cardiovasc Surg(�л�����Ѫ�������־), 2013, 29(12):767-768. JOHNSON D C, KAPLAN L J. Perioperative pulmonary complications . Curr Opin Crit Care, 2011, 17(4):362-369. CHEN X Q, WANG Z, LI X. Efficacy of high-dose ambroxol hydrochloride in aspiration pneumonia in elderly patients with aspirootion pneumonias. Chin J Geriatr(�л�����ҽѧ��־), 2012, 31(4):299-301. WANG X, WANG L. Lung protection of high-dose ambroxol hydrochloride in perioperative period of lung cancer . Chin J Thorac Cardiovasc Surg(�л�����Ѫ�������־), 2013, 29(2):127-128. LAOAG-FERNANDEZ J B, FERNANDEZ A M, MARUO T. Antenatal use of ambroxol for the prevention of infant respiratory distress syndrome . J Obstet Gynaecol Res, 2000, 26(4):307-312. ZHENG Y H, KUANG S J. Effect of small and large ambroxol on pulmonary surfactant in asthma guinea-pig . J Chin Physician (�й�ҽʦ��־), 2003, (suppl l):5-6. CHEN Y, MA B, YANG K H, et al. Ambroxol hydrochloride for lung protection in perioperative period:A systematic review . Chin J Evid-Based Med(�й�ѭ֤ҽѧ��־), 2009, 9(5):558-564. XU S. Progress in the clinical application of ambroxol . J Clin Pulm Med (�ٴ��ο���־), 2009, 14(8):1053-1055. SHI G, CHEN H W, LIU F Q. Early intervention in preventing the neonatol hyaline membrane disease . Clin Med China (�й��ۺ��ٴ�), 2002, 18(2):191-192. CUI Y H. Analysis of clinical effects of ambroxol hydrochloride by different ways in the treatment of pneumonia . Chin J Mod Drug Appl (�й��ִ�ҩ��Ӧ��), 2013, 7(21):163-164. LI J, YU R H, HUANG Y P, et al. Clinical effects of Mucosolvan by two ways in treating chronic obstructive pulmonary disease at the stage of acute exacerbation . J Clin Pulmen Med (�ٴ��ο���־), 2007, 12(11):1169-1170. JIN Y, WANG L, ZHAO B J, et al. Effects of Mucosolvan administrated by different routes on lung functions in patients with cardiopulmonary bypass:A comparison study . Contemp Med (����ҽѧ), 2012, 18(7):11-13. HU Q, LIAN J M, LI J Q. Efficacy of intravenous or atomizing ambroxol for prevention of respiratory distress syndrome in preterm infants . Chin J Contemp Pediatr(�й�����������־), 2006, 8(4):301-303. LIN Y J, YANG L, ZHOU J X. Meta analysis of different administration pathways of ambroxol for treating lower respiratory tract infections in children . Chin Pharm(�й�ҩҵ), 2012, 21(8):23-26. LOU H G, LIU F, ZHAI S D. Aerosol inhalation of ambroxol for pneumonia:A systematic review . Chin J Evid-Based Med (�й�ѭ֤ҽѧ��־), 2006, 6(5):421-429.
2015, Vol. 50 
